AMOEBA (EPA:ALMIB) - AMOEBA ANNOUNCES THE APPOINTMENT OF PIERRE MORGON AS CENSEUR ON THE BOARD OF DIRECTORS

Transparency directive : regulatory news

17/12/2020 17:45

PRESS RELEASE

AMOEBA ANNOUNCES THE APPOINTMENT OF PIERRE MORGON AS CENSEUR ON THE BOARD OF
                                   DIRECTORS

Chassieu (France), December 17 2020 - 5.45 pm- AMOEBA (FR0011051598 - ALMIB),
the Board of Directors of Amoeba, at its meeting of 17 December 2020, appointed
Pierre Morgon as non-voting Director with a view to proposing his candidacy as
Director at the next General Meeting of Shareholders to be held in 2021. As a
non-voting director, he will attend the next meetings of the Board of Directors
in an advisory capacity, bringing his extensive experience and expertise to the
Company.

Experiences and training

Pierre Morgon has over 30 years of experience in the global Life Sciences
industry, especially specialty care, vaccines and immunotherapy, in management
positions in multinational companies and as CEO of start-up companies.

He is a lecturer in several MBA programs and life sciences conferences, as well
as at the Mass Challenge incubator in Switzerland where he also acts as a
mentor for life sciences start-ups.

Currently, Pierre MORGON is CEO of MRGN Advisors, Regional Partner for
Switzerland at Mérieux Equity Partners and Senior Vice-President International
Business at CanSino Biologics.

He is also Chairman of the Boards of Directors of Theradiag, Eurocine Vaccines,
MYCB1 and Health Technology Holding, as well as Non-Executive Director of the
Boards of Directors of Vaccitech and Univercells.

He holds a doctorate in pharmacy, a master's degree in business law and a MBA.
He is also an alumnus of ESSEC, INSEAD and IMD.

"I would like to thank Fabrice Plasson for the confidence he has shown in me by
asking me to join Amoeba's Board of Directors. The company is in full expansion
and the new applications of its technology in human health represent an
exciting opportunity and challenge. I look forward to bringing my experience in
life sciences, both in terms of development, partnerships and business
development as well as governance" said Pierre MORGON.

"Pierre is a global reference in the field of vaccines and immunotherapies as
well as in the entire value chain of the healthcare industry. It is a great
pleasure to welcome him to our Board of Directors to benefit from his
international vision (Chinese, European and American) in this sector. Pierre is
also a recognized director of listed companies in Europe and an investment fund
manager, with a perfect understanding of the challenges faced by companies such
as Amoeba, which are undergoing strong acceleration," said Fabrice Plasson,
Chairman and CEO of Amoeba.

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on Euronext Growth. The Company is
a member of the BPIfrance Excellence network and is eligible for the PEA-PME
SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
      MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
     Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba
Valérie FILIATRE
Directeur Général Adjoint
+33 4 26 69 16 00
v.filiatre@amoeba-nature.com

Calyptus
Relations investisseurs & Presse
Grégory BOSSON / Mathieu CALLEUX
+33 1 53 65 37 90 /91
amoeba@calyptus.net

Disclaimer
This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the Universal
Registration Document of AMOEBA filed with the French Financial Markets
Authority (Autorité des Marchés Financiers) on April 30, 2020 under number
D20-0416 (a copy of which is available on www.amoeba-biocide.com). The
forward-looking statements contained in this press release are also subject to
risks not yet known to AMOEBA or not currently considered material by AMOEBA.
The occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of AMOEBA to be materially
different from such forward-looking statements.

Adresse: 38 Avenue des Frères Montgolfier, 69680 CHASSIEU
Société Anonyme au capital de 311578,38 EUR
RCS Lyon 523877 215

Tel: +33 (0)4 26 69 16 00 ? Email: contact@amoeba-nature.com
Linkedin: @amoeba-nature ?Twitter: @AmoebaNature
www.amoeba-nature.com

AMOEBA's latest news

28/03/2024 18:30

AMOEBA (EPA:ALMIB) - AMOEBA ANNOUNCES THE APPOINTMENT OF PIERRE MORGON AS CENSEUR ON THE BOARD OF DIRECTORS

Transparency directive : regulatory news

AMOEBA's latest news

Other stories